Ex vivo expansion of hematopoietic stem and progenitor cells: Recent advances  

作　　者：Katsuhiro Kita Fangming Xiu Marc G Jeschke 

机构地区：[1]Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch [2]Sunnybrook Research Institute, University of Toronto [3]Ross Tilley Burn Centre, Sunny brook Health Science Centre and Sunnybrook Research Institute and Division of Plastic Surgery, Department of Surgery, University of Toronto

出　　处：《World Journal of Hematology》2014年第2期18-28,共11页世界血液学杂志

基　　金：Supported by Canadian Institutes of Health Research,No.123336;CFI Leader’s Opportunity Fund,No.25407;Physicians’ Services Incorporated Foundation-Health Research Grant Program(MGJ)

摘　　要：Hematopoietic stem cells(HSCs) have become the most extensively studied stem cells and HSC-based cellular therapy is promising for hematopoietic cancers and hereditary blood disorders. Successful treatment of patients with HSC cells depends on sufficient number of highly purified HSCs and progenitor cells. However, stem cells are a very rare population no matter where they come from. Thus, ex vivo amplification of these HSCs is essential. The heavy demands from more and more patients for HSCs also require industrial-scale expansion of HSCs with lower production cost and higher efficiency. Two main ways to reach that goal:(1) to find clinically applicable, simple and efficient methods(or reagents) to enrich HSCs;(2) to find new developmental regulators and chemical compounds in order to replace the currently used cytokine cocktails for HSCsamplification. In this Editorial review, we would like to introduce the current status of ex vivo expansion of HSCs, particularly focusing on enrichment and culture supplements.Hematopoietic stem cells(HSCs) have become the most extensively studied stem cells and HSC-based cellular therapy is promising for hematopoietic cancers and hereditary blood disorders. Successful treatment of patients with HSC cells depends on sufficient number of highly purified HSCs and progenitor cells. However, stem cells are a very rare population no matter where they come from. Thus, ex vivo amplification of these HSCs is essential. The heavy demands from more and more patients for HSCs also require industrial-scale expansion of HSCs with lower production cost and higher efficiency. Two main ways to reach that goal:(1) to find clinically applicable, simple and efficient methods(or reagents) to enrich HSCs;(2) to find new developmental regulators and chemical compounds in order to replace the currently used cytokine cocktails for HSCsamplification. In this Editorial review, we would like to introduce the current status of ex vivo expansion of HSCs, particularly focusing on enrichment and culture supplements.

关 键 词：HEMATOPOIETIC STEM CELL Ex vivo expansion SERUM-FREE culture CELL surface MARKERS ENRICHMENT STEM CELL isolation 

分 类 号：R[医药卫生]